Crinetics Pharmaceuticals IncNASDAQ:CRNX
- LAST PRICE58.9000
- TODAY'S CHANGE (%)-1.1100 (-1.8497%)
- Bid / Lots58.8100/ 8
- Ask / Lots58.9500/ 8
- Open / Previous Close59.9900 / 60.0100
- Day Range
- 52 Week Range
- Volume259,240
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRNX |
|---|---|---|
| 09:32 ET | 2728 | 59.52 |
| 09:35 ET | 1223 | 60.24 |
| 09:37 ET | 872 | 60.39 |
| 09:44 ET | 200 | 60.25 |
| 09:46 ET | 1100 | 60.25 |
| 09:48 ET | 1783 | 60.295 |
| 09:50 ET | 454 | 60.3 |
| 09:51 ET | 440 | 60.4725 |
| 09:53 ET | 600 | 60.305 |
| 09:55 ET | 1124 | 60.01 |
| 09:57 ET | 1275 | 60.135 |
| 10:00 ET | 600 | 60.195 |
| 10:02 ET | 700 | 60.21 |
| 10:04 ET | 500 | 60.19 |
| 10:06 ET | 400 | 60.205 |
| 10:08 ET | 3600 | 59.81 |
| 10:09 ET | 3487 | 60.14 |
| 10:13 ET | 963 | 60.275 |
| 10:15 ET | 4450 | 60.23 |
| 10:18 ET | 1606 | 59.855 |
| 10:20 ET | 3644 | 59.5 |
| 10:22 ET | 730 | 59.706313 |
| 10:24 ET | 400 | 59.63 |
| 10:26 ET | 300 | 59.585 |
| 10:27 ET | 840 | 59.44 |
| 10:29 ET | 100 | 59.54 |
| 10:31 ET | 400 | 59.5 |
| 10:33 ET | 392 | 59.387199 |
| 10:36 ET | 3730 | 59.455 |
| 10:38 ET | 1201 | 59.29 |
| 10:40 ET | 300 | 59.315 |
| 10:42 ET | 900 | 59.24 |
| 10:44 ET | 100 | 59.31 |
| 10:45 ET | 100 | 59.14 |
| 10:47 ET | 14374 | 59.36 |
| 10:49 ET | 1828 | 59.3 |
| 10:51 ET | 1523 | 59.34 |
| 10:54 ET | 6305 | 59.375 |
| 10:56 ET | 2035 | 59.4 |
| 10:58 ET | 11364 | 59.32 |
| 11:00 ET | 100 | 59.36 |
| 11:03 ET | 2370 | 59.345 |
| 11:05 ET | 200 | 59.33 |
| 11:07 ET | 700 | 59.23 |
| 11:12 ET | 9186 | 59.25 |
| 11:14 ET | 2721 | 59.29 |
| 11:16 ET | 47402 | 58.97 |
| 11:20 ET | 1599 | 59.1 |
| 11:25 ET | 800 | 58.96 |
| 11:27 ET | 1000 | 59.19 |
| 11:30 ET | 157 | 59.15 |
| 11:32 ET | 2587 | 59.185 |
| 11:34 ET | 456 | 59.19 |
| 11:36 ET | 1200 | 59.17 |
| 11:38 ET | 600 | 59.22 |
| 11:41 ET | 100 | 59.235 |
| 11:43 ET | 1209 | 59.02 |
| 11:45 ET | 100 | 59.02 |
| 11:48 ET | 100 | 59.01 |
| 11:50 ET | 1300 | 59.13 |
| 11:52 ET | 100 | 59.15 |
| 11:54 ET | 1000 | 59.305 |
| 11:56 ET | 600 | 59.26 |
| 11:57 ET | 234 | 59.1 |
| 11:59 ET | 100 | 59.1 |
| 12:01 ET | 900 | 58.97 |
| 12:03 ET | 100 | 59.085 |
| 12:06 ET | 600 | 59.08 |
| 12:08 ET | 500 | 59.12 |
| 12:10 ET | 300 | 59.04 |
| 12:12 ET | 210 | 59 |
| 12:14 ET | 854 | 59.015 |
| 12:15 ET | 500 | 58.99 |
| 12:17 ET | 9900 | 59.08 |
| 12:19 ET | 200 | 59.02 |
| 12:21 ET | 5397 | 59.22 |
| 12:26 ET | 300 | 59.29 |
| 12:28 ET | 912 | 59.22 |
| 12:30 ET | 100 | 59.26 |
| 12:32 ET | 1287 | 59.22 |
| 12:33 ET | 100 | 59.22 |
| 12:35 ET | 700 | 59.23 |
| 12:37 ET | 2022 | 59.14 |
| 12:39 ET | 200 | 59.11 |
| 12:42 ET | 3453 | 59.085 |
| 12:44 ET | 1158 | 59 |
| 12:46 ET | 200 | 58.995 |
| 12:48 ET | 1359 | 58.94 |
| 12:50 ET | 300 | 58.95 |
| 12:51 ET | 800 | 58.91 |
| 12:53 ET | 5291 | 58.9 |
| 12:55 ET | 300 | 58.87 |
| 12:57 ET | 600 | 58.765 |
| 01:00 ET | 1200 | 58.76 |
| 01:02 ET | 100 | 58.825 |
| 01:04 ET | 100 | 58.9 |
| 01:06 ET | 1000 | 58.95 |
| 01:08 ET | 690 | 58.935 |
| 01:09 ET | 271 | 58.9 |
Yesterday
Oct 16, 2024
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024, from 8:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Crinetics Pharmaceuticals Inc | 5.4B | -15.6x | --- |
Avidity Biosciences Inc | 5.5B | -16.1x | --- |
Biohaven Ltd | 5.2B | -5.5x | --- |
BridgeBio Pharma Inc | 4.9B | -9.2x | --- |
Krystal Biotech Inc | 5.6B | 106.8x | --- |
Nuvalent Inc | 6.2B | -32.4x | --- |
Company Information
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Contact Information
- Headquarters
- 10222 Barnes Canyon Rd Bldg 2SAN DIEGO, CA, United States 92121-2711
- Phone
- 858-450-6464
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Wendell Wierenga
- Co-Founder, Director
- R. Scott Struthers
- Co-Founder, Chief Scientific Officer
- Stephen Betz
- Chief Financial Officer
- Marc Wilson
- Chief Operating Officer
- Jeff Knight
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.4B |
|---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 89.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.61 |
EPS | $-3.77 |
Book Value | $7.91 |
P/E Ratio | -15.6x |
Price/Sales (TTM) | 3,870.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -20,068.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
